4.7 Review

Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.630536

Keywords

nuclear receptors; inflammasome; inflammatory disease; circadian rhythm; NLRP3; therapeutic strategy; inflammation and innate immunity

Funding

  1. Fondation pour la Recherche Medicale (FRM) [EQU202003010310]
  2. INSERM
  3. ANR-Labex-EGID (EGID) [ANR-10-LABX-46]
  4. Fondation Francophone pour la recherche sur le diabete (FFRD)
  5. Federation Francaise des Diabetiques (AFD) AstraZeneca
  6. Eli Lilly
  7. Merck Sharp amp
  8. Dohme (MSD)
  9. Novo Nordisk amp
  10. Sanofi
  11. Region Hauts-de-France/FEDER (Chronoregeneration)
  12. Association Francaise contre les Myopathies (AFM)
  13. Fondation de France
  14. Societe Francophone du Diabete (SFD)-SERVIER
  15. ANR
  16. European Union under the European Region Development Fund (ERDF)
  17. Hauts de France Region Council [20000007, 20002842]
  18. MEL [2020-ESR-02, 2020-ESR-06]
  19. French State [2019-R3-CTRL_IPL_Phase3, 2020-R3-CTRL_IPL_Phase4]
  20. Agence Nationale pour la Recherche (ANR) [ANR-19-CE15-0033-01]

Ask authors/readers for more resources

The inflammasome, a master regulator of the innate immune system especially in macrophages, plays a key role in maintaining cellular health by cleaving pro-inflammatory cytokines in response to cytolytic pathogens or stress signals. Dysregulation of inflammasomes can lead to critical diseases, but they are tightly controlled by a two-step activation process involving transcription and complex formation. Recent studies have suggested nuclear receptors as additional regulators of this pathway, with potential benefits for inflammatory disease treatment.
The innate immune system is the first line of defense specialized in the clearing of invaders whether foreign elements like microbes or self-elements that accumulate abnormally including cellular debris. Inflammasomes are master regulators of the innate immune system, especially in macrophages, and are key sensors involved in maintaining cellular health in response to cytolytic pathogens or stress signals. Inflammasomes are cytoplasmic complexes typically composed of a sensor molecule such as NOD-Like Receptors (NLRs), an adaptor protein including ASC and an effector protein such as caspase 1. Upon stimulation, inflammasome complex components associate to promote the cleavage of the pro-caspase 1 into active caspase-1 and the subsequent activation of pro-inflammatory cytokines including IL-18 and IL-1 beta. Deficiency or overactivation of such important sensors leads to critical diseases including Alzheimer diseases, chronic inflammatory diseases, cancers, acute liver diseases, and cardiometabolic diseases. Inflammasomes are tightly controlled by a two-step activation regulatory process consisting in a priming step, which activates the transcription of inflammasome components, and an activation step which leads to the inflammasome complex formation and the subsequent cleavage of pro-IL1 cytokines. Apart from the NF-kappa B pathway, nuclear receptors have recently been proposed as additional regulators of this pathway. This review will discuss the role of nuclear receptors in the control of the NLRP3 inflammasome and the putative beneficial effect of new modulators of inflammasomes in the treatment of inflammatory diseases including colitis, fulminant hepatitis, cardiac ischemia-reperfusion and brain diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available